Table 2. Association of concentration of cfDNA and fragmentation pattern with clinicopathological characteristics in advanced or metastatic NSCLC TKI-naïve patients.
| Characteristics | Median cfDNA concentration (ng/mL) |
P value | Median cfDNA, 100–250 bp (%) (mean size ± SD) | P value | Median cfDNA, 250–700 bp (%) (mean size ± SD) | P value |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 28.8 | NS | 39.0 (175.3±5.6) | NS | 17.0 (436.7±34.8) | NS |
| Female | 27.8 | 45.0 (174.1±4.9) | 15.0 (423.9±58.3) | |||
| Smoking history | ||||||
| Current smokers | 36.6 | NS | 43.0 (174.9±4.9) | NS | 15.0 (438.0±44.5) | NS |
| Former smokers | 26.0 | 38.0 (175.2±6.1) | 17.0 (435.2±30.4) | |||
| Never smokers | 33.1 | 44.0 (174.0±4.1) | 16.0 (419.1±65.6) | |||
| Histology and stage of the disease | ||||||
| ADK patients | 27.1 | NS | 41.0 (175.0±4.8) | NS | 16.0 (429.0±50.0) | NS |
| Other NSCLC patients | 35.8 | 44.0 (173.8±7.1) | 17.0 (437.7±34.7) | |||
| ADK III patients | 13.1 | <0.0001 | 24.5 (178.0±4.1) | 0.008 | 10.5 (434.1±39.0) | 0.02 |
| ADK IV patients | 29.0 | 41.0 (174.7±4.8) | 16.0 (428.6±50.9) | |||
| Other NSCLC III patients | 12.8 | <0.0001 | 41.0 (179.8±4.2) | NS | 18.0 (448.6±8.10) | NS |
| Other NSCLC IV patients | 41.1 | 45.0 (172.3±6.9) | 17.0 (435.0±38.3) | |||
| All stage III patients | 13.1 | <0.0001 | 33.0 (178.7±4.1) | 0.013 | 14.0 (439.7±31.0) | NS |
| All stage IV patients | 31.9 | 43.0 (174.3±5.2) | 16.0 (429.6±49.0) |
ADK, (adenocarcinoma); NSCLC, non-small cell lung cancer (includes non-adenoid cystic carcinoma, pulmonary pleomorphic carcinoma, unknown primary side cancer, squamous cell carcinoma and NSCLC-non-otherwise specified); NS, no significant, P value.